Johnson & Johnson

Deutsche Bank has published a report on Johnson & Johnson (NYSE: JNJ) maintaining a HOLD rating for the massive holding company. In the report, Deutsche Bank wrote, "J&J's 2Q11 sales were higher than expected mainly due to FX as underlying growth was similar to 1Q11 adjusting for easy...

Morgan Stanley has published a report on Johnson & Johnson (NYSE: JNJ) broadly commenting on the company. In the report, Morgan Stanley wrote, "We're not overly alarmed by 2H11 EBIT shortfall. Though the quarter does raise some questions on long-term leverage potential, the reduction in...

Earnings season ramps up this week with quarterly reports due from the likes of tech companies such as IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT), big banks such as Wells Fargo (NYSE: WFC) and Bank of America (NYSE: BAC), and consumer goods giants such as PepsiCo (NYSE: PEP) and Johnson &...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

First Trust Consumer Staples AlphaDEX (NYSE: FXG) is up more than 20% year to date. The investment seeks results that correspond generally to the price and yield of an equity index called the StrataQuant Consumer Staples Index. Top holdings include Green Mountain Coffee Roasters (NASDAQ: GMCR),...

Deutsche Bank is out with its report today on Johnson & Johnson (NYSE: JNJ), initiating JNJ at Hold. In a note to clients, Deutsche Bank writes, "We believe J&J's pharma pipeline is well understood and do not see any major differences between our forecast and consensus. The exit of...

According to Piper Jaffray, Johnson & Johnson (NYSE: JNJ) Neutral rating is maintained. Piper Jaffray said that, after a long wait, the approval of Xarelto for the prevention of DVT following knee and hip replacement comes as a bit of a relief, two years after an FDA panel recommended approval...

Morgan Stanley provided color on Johnson & Johnson (NYSE: JNJ). In a research report published today, Morgan Stanley commented on the company's new product Xarelto. In the report, Morgan Stanley states, "Positive apixaban data in the ARISTOTLE trial may decrease commercial potential for J...

  MAKING THE VALUE PROPOSITION FOR STAR SCIENTIFIC Tobacco could kill one billion people this century -(Reuters) Part one: CigRx™, the over-the-counter nutraceutical that reduces the urge to smoke. My recent reports on Star Scientific have dealt largely with...

Goldman Sachs is out with its report today on Johnson & Johnson (NYSE: JNJ), maintaining Buy. In a note to clients, Goldman Sachs writes, "We continue to see JNJ as the best underappreciated new product story in Pharma, with the only accelerating earnings trajectory over the next three years...

According to Daiwa Capital Markets, Johnson & Johnson (NYSE: JNJ) updated investors on its Pharmaceutical new product plan. Daiwa said that it rates JNJ 2. “We expect drug sales to be up 10.3% this year and 8.2% in 2012, driven by recently introduced drugs and by products currently in the...

First Global has upgraded Johnon & Johnson (NYSE: JNJ) to Moderate Outperform.

According to a recent article from Morgan Stanley, Johnson & Johnson (NYSE: JNJ) has estimated a lead in the pharma industry for total drug sales launched in 2009- 11. JNJ reported these sales have totaled over $1.1 billion. In the report, Morgan Stanley said, "We expect this momentum to...

According to Goldman Sachs, Johnson & Johnson's (NYSE: JNJ) Pharma Analyst Day reinforced Goldman's conviction in JNJ as the best new product story in the global drug sector, given its dominant positions in the largest and fastest growing categories. Goldman Sachs said that many of JNJ's new...

Johnson & Johnson (NYSE: JNJ) hosted an analyst meeting recently, which, according to J.P. Morgan, “highlights [a] reinvigorated pipeline.” “J&J hosted its bi-annual Pharmaceutical analyst meeting Thursday in New Brunswick,” J.P. Morgan writes. “At the meeting, management highlighted its...